Browsing by Author "Bath, Philip M."

Now showing items 1-3 of 3

    • Applicability of ENCHANTED trial results to current acute ischemic stroke patients eligible for intravenous ... 
      Robinson, Thompson G.; Bray, Benjamin D.; Paley, Lizz; Sprigg, Nikola; Wang, Xia; Arima, Hisatomi; Bath, Philip M.; Broderick, Joseph P.; Durham, Alice C.; Kim, Jong S.; Lavados Germain, Pablo Manuel; Lee, Tsong Hai; Martins, Sheila; Nguyen, Thang H.; Pandian, Jeyaraj D.; Parsons, (SAGE Publications Inc., 2019)
      Background: Randomized controlled trials provide high-level evidence, but the necessity to include selected patients may limit the generalisability of their results. Methods: Comparisons were made of baseline and outcome ...
    • Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke ... 
      Anderson, Craig S.; Huang, Yining; Lindley, Richard I.; Chen, Xiaoying; Arima, Hisatomi; Chen, Guofang; Li, Qiang; Billot, Laurent; Delcourt, Candice; Bath, Philip M.; Broderick, Joseph P.; Demchuk, Andrew M.; Donnan, Geoffrey A.; Durham, Alice C.; Lavados Germain, Pablo Manuel (Lancet Publishing Group, 2019)
      Background: Systolic blood pressure of more than 185 mm Hg is a contraindication to thrombolytic treatment with intravenous alteplase in patients with acute ischaemic stroke, but the target systolic blood pressure for ...
    • Lipid-Lowering pretreatment and outcome following intravenous thrombolysis for acute ischaemic stroke: A ... 
      Minhas, Jatinder S.; Wang, Xia; Arima, Hisatomi; Bath, Philip M.; Billot, Laurent; Broderick, Joseph P.; Donnan, Geoffrey A.; Kim, Jong S.; Lavados Germain, Pablo Manuel; Lee, Tsong-Hai; Martins, Sheila Cristina Ouriques; Olavarría, Verónica V.; Pandian, Jeyaraj D.; Pontes Neto, Octavio Marques; Ricci, Stefano; Sato, Shoichiro; Sharma, Vijay K.; Thang, Nguyen H.; Wang, Ji-Guang; Woodward, Mark; Chalmers, John; Anderson, Craig S.; Robinson, Thompson G. (Karger, 2018)
      Background: Debate exists as to whether statin pretreatment confers an increased risk of 90-day mortality and symptomatic intracranial haemorrhage (sICH) in acute ischaemic stroke (AIS) patients treated with intravenous ...